Dr. Sonneborn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
789 Central Ave
Dover, NH 03820Phone+1 603-742-8787Fax+1 603-740-2446
Education & Training
- University of Utah HealthFellowship, Hematology and Medical Oncology, 1977 - 1979
- Albany Medical CenterResidency, Internal Medicine, 1975 - 1977
- Albany Medical CenterInternship, Internal Medicine, 1974 - 1975
- Albany Medical CollegeClass of 1974
Certifications & Licensure
- NH State Medical License 1979 - 2025
- ME State Medical License Active through 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Publications & Presentations
PubMed
- 14 citationsPhase II study of aclarubicin in acute myeloblastic leukemia.Delvyn C. Case, Thomas J. Ervin, Marjorie A. Boyd, Louis G. Bove, Henry Sonneborn
American Journal of Clinical Oncology. 1987-12-01 - 30 citationsCombined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.Jacob J. Lokich, Henry Sonneborn, Norwood R. Anderson, Murray M. Bern, Frank V. Coco
Cancer. 1999-06-01 - 4 citationsAdriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer.Harry W. Matelski, Jacob J. Lokich, Mark S. Huberman, Zipoli T, Paul S
American Journal of Clinical Oncology. 1984-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: